Home

TLDR Biotech

The top stories in biotech & pharma, straight to your inbox in only one email.
Trusted by 2700+ biotech and pharma professionals.

Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.

TLDR Biotech

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | April 22 - 23, 2026

Apr 24, 2026

•

3 min read

Biotech & Pharma Updates | April 22 - 23, 2026

🧬 Kurma Partners closes €215M ($251M) Biofund IV to back around 20 European biotechs, Regeneron Pharmaceuticals' Otarmeni wins FDA approval for otoferlin-deficient congenital hearing loss following Ph1/2 success, Evonik invests €80M ($93.6M) in Slovakia facility to boost fermentation capabilities - adding 50 jobs, Novo Nordisk's Rybelsus (semaglutide) meets Ph3 goals in pediatric type 2 diabetes + supporting label expansion filings

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 21 - 22, 2026

Apr 23, 2026

•

3 min read

Biotech & Pharma Updates | April 21 - 22, 2026

🧬 Merck & Co. + Google Cloud partner on enterprise-wide agentic AI transformation, investment valued up to $1B, AbbVie invests $1.4B to build 185-acre Durham NC production hub - creating 730-plus jobs, Amneal acquires Kashiv BioSciences for $1.1B to expand biosimilars pipeline amid market growth, Moderna's mCOMBRIAX (mRNA-1010/mNEXSPIKE) wins European Commission approval for influenza and COVID-19 combination immunization in adults 50 and older

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 20 - 21, 2026

Apr 22, 2026

•

3 min read

Biotech & Pharma Updates | April 20 - 21, 2026

🧬 Ray Therapeutics raises $125M Series B for genetic retinal degeneration gene therapy, Flagship Pioneering launches Serif Biomedicines with $50M to develop novel modified DNA genetic medicines, AstraZeneca's Ultomiris (ravulizumab) meets primary endpoint in Ph3 trial for immunoglobulin A nephropathy, Merck & Co.'s Idvynso (doravirine/islatravir) wins FDA approval for virologically suppressed adults with human immunodeficiency virus following Ph3 success

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 19 - 20, 2026

Apr 21, 2026

•

4 min read

Biotech & Pharma Updates | April 19 - 20, 2026

🧬 Eli Lilly acquires Kelonia Therapeutics for up to $7B to expand in vivo CAR-T capabilities, AstraZeneca's (tozorakimab) meets primary endpoint in Ph3 trial for chronic obstructive pulmonary disease, Biogen + TJ Biopharma expand partnership for China rights to felzartamab - $100M upfront + $850M biobucks

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 16 - 19, 2026

Apr 20, 2026

•

3 min read

Biotech & Pharma Updates | April 16 - 19, 2026

🧬 Former Genentech leader unveils Synthetic Design Lab - developing adaptive "smart" ADC cancer drugs, UCB to acquire Neurona Therapeutics for up to $1.2B - expanding into seizure cell therapy, Merck & Co. unveils Ph1/Ph2 data for MK-2010 (MK-2010) - PD-1xVEGF bispecific in non-small cell lung cancer

Anis Fahandej-Sadi

The China Factor: Synthetic Biology's Shifting Global Landscape

Apr 18, 2026

•

4 min read

The China Factor: Synthetic Biology's Shifting Global Landscape

🧬 From policy to production: how China is scaling synthetic biology - and what it means for global competition

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 15 - 16, 2026

Apr 17, 2026

•

3 min read

Biotech & Pharma Updates | April 15 - 16, 2026

🧬 Kailera Therapeutics prices massive $625M IPO for advancing next-generation obesity care treatments, Roche launches new Phase III study to pursue EU approval for DMD gene therapy Elevidys, Aligos Therapeutics + Amoytop ink $445M deal licensing HBV drug pevifoscorvir sodium China rights

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 14 - 15, 2026

Apr 16, 2026

•

3 min read

Biotech & Pharma Updates | April 14 - 15, 2026

🧬 Spain plans $200M VC fund bridging Spanish biotechs with Boston's life science ecosystem, Beeline Medicines debuts with $300M Series A - licensing five Bristol Myers immune disease drug candidates, Sandoz signs manufacturing and supply agreement with Rwanda government to provide critical medicines across Africa

Anis Fahandej-Sadi

Biotech & Pharma Updates | April 13 - 14, 2026

Apr 15, 2026

•

8 min read

Biotech & Pharma Updates | April 13 - 14, 2026

🧬 Novo Nordisk + OpenAI partner to integrate AI across drug discovery + manufacturing + corporate operations, Amazon Web Services launches Amazon Bio Discovery AI tool to accelerate antibody design and drug discovery, Eli Lilly acquires CrossBridge Bio for up to $300M to advance dual-payload ADC cancer pipeline, Alamar Biosciences files for $159M IPO - protein sequencing and biomarker profiling tools, Harbinger Health raises $100M to develop RESOLVE multi-cancer liquid biopsy detection tests

Anis Fahandej-Sadi

...

The Latest Biotech & Pharma Updates

Biotech & Pharma Updates | April 22 - 23, 2026

Biotech & Pharma Updates | April 21 - 22, 2026

Biotech & Pharma Updates | April 20 - 21, 2026

Biotech & Pharma Updates | April 19 - 20, 2026

Biotech & Pharma Updates | April 16 - 19, 2026

The China Factor: Synthetic Biology's Shifting Global Landscape

Biotech & Pharma Updates | April 15 - 16, 2026

Biotech & Pharma Updates | April 14 - 15, 2026

Biotech & Pharma Updates | April 13 - 14, 2026

TLDR Biotech

FAQ

Media Partners